激肽釋放酶原(PK)重組蛋白
Recombinant Prekallikrein (PK)
KLKB1; KLK3; Fletcher Factor; Kallikrein B,Plasma; Kininogenin; Plasma prekallikrein
- 編號RPB801Hu01
- 物種Homo sapiens (Human，人)相同的名稱，不同的物種。
- 來源原核表達(dá)
- 宿主E.coli
- 內(nèi)毒素水平<1.0EU/µg(LAL法測定)
- 亞細(xì)胞定位分泌
- 預(yù)測分子量26.9kDa
- 實(shí)際分子量27kDa(差異分析請參閱說明書)
- 片段與標(biāo)簽Thr156~Thr364 with N-terminal His Tag
- 緩沖液成份PBS, pH7.4, containing 0.01% SKL, 5% Trehalose.
- 性狀凍干粉
- 純度> 95%
- 等電點(diǎn)8.2
- 應(yīng)用Positive Control; Immunogen; SDS-PAGE; WB.
如果需要有生物活性的蛋白，請參見活性蛋白。 - 下載英文說明書 中文說明書
- 規(guī)格10μg50μg200μg1mg5mg
- 價格¥ 1080¥ 2700¥ 5400¥ 16200¥ 40500
- 欲了解實(shí)際交易價格和更多情況，請與當(dāng)?shù)亟?jīng)銷商聯(lián)系!
產(chǎn)品包裝(模擬)
產(chǎn)品包裝(模擬)
SDS-PAGE圖
通過ISO 9001、ISO 13485質(zhì)量體系認(rèn)證
序列
用法
Reconstitute in 10mM PBS (pH7.4) to a concentration of 0.1-1.0 mg/mL. Do not vortex.
儲存
避免反復(fù)凍融。2-8°C不超過一個月，-80°C不超過12個月。
穩(wěn)定性
熱穩(wěn)定性以損失率顯示。損失率是由加速降解試驗(yàn)決定，具體方法如下：在37°C孵育48小時，沒有顯著的降解或者沉淀產(chǎn)生。保質(zhì)期內(nèi)，在適當(dāng)?shù)臈l件下存儲，損失率低于5%。
增值服務(wù)
相關(guān)產(chǎn)品
| 編號 | 適用物種：Homo sapiens (Human，人) | 應(yīng)用(僅供研究使用，不用于臨床診斷！) |
| RPB801Hu01 | 激肽釋放酶原(PK)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| PAB801Hu01 | 激肽釋放酶原(PK)多克隆抗體 | WB; IHC; ICC; IP. |
| MAB801Hu22 | 激肽釋放酶原(PK)單克隆抗體 | WB; IHC; ICC; IP. |
| SEB801Hu | 激肽釋放酶原(PK)檢測試劑盒(酶聯(lián)免疫吸附試驗(yàn)法) | Enzyme-linked immunosorbent assay for Antigen Detection. |
| LMB801Hu | 激肽釋放酶原(PK)等多因子檢測試劑盒(流式熒光發(fā)光法) | FLIA Kit for Antigen Detection. |
參考文獻(xiàn)
| 雜志 | 參考文獻(xiàn) |
| Int J Immunopathol Pharmacol | Altered activities of kininase II, an angiotensin converting enzyme, prekallikrein, and nitric oxide in Kuwaiti patients with type 2 diabetes[PubMed: 25964383] |
| Thromb Res | Factor XII–mediated contact activation related to poor prognosis in disseminated intravascular coagulation[PubMed: 26706311] |
| Thrombosis Research | Factor XII-mediated contact activation related to poor prognosis in disseminated intravascular coaCavia (Guinea pig )lation[Pubmed:26706311] |
| Annals of Laboratory Medicine | The First Case of Congenital Prekallikrein Deficiency in Korea With a Novel Pathogenic Variant (c. 1198G> T)[Pubmed: 30430790] |
| J Cell Mol Med | Huaier shows anti?\cancer activities by inhibition of cell growth, migration and energy metabolism in lung cancer through PI3K/AKT/HIF?\1|á pathway[33377619] |
| J Thromb Thrombolysis | Contact system activation in disseminated intravascular coagulation: activities of prekallikrein and high-molecular-weight kininogen are significant risk factors[Pubmed:34993714] |